IP Library Granted Patent US 7,670,491
Granted Patent B2
US 7,670,491 · App. 10/606,150 · Granted Mar 2, 2010

Buffered compositions for dialysis

Assignee: Advanced Renal Technologies
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,670,491
App. No.
10/606,150
Granted
Mar 2, 2010
Kind
B2
Abstract

Acid concentrates, and dialysate compositions prepared therefrom, contain citric acid and an effective amount of a buffering agent selected from acetate and/or lactate. The buffering agent allows a physiologically acceptable amount of citrate to maintain the desired pH of the dialysate.

Claims (12)

1. A dialysate precursor composition comprising citrate at a concentration ranging from about 20 to about 900 mEq/L; a buffering anion selected from acetate and/or lactate; water; chloride at a concentration ranging from about 1,000 to about 7,000 mEq/L; at least one physiologically-acceptable cation; and a therapeutically effective amount of ferric form of iron.

2. The dialysate precursor composition of claim 1 wherein the buffering anion is at a concentration ranging from about 0.01 to about 150 mEq/L.

3. The dialysate precursor composition of claim 1 comprising citrate at a concentration ranging from about 70 to about 150 mEq/L.

4. The dialysate precursor composition of claim 1 wherein the buffering anion is at a concentration ranging from about 0.3 to about 125 mEq/L.

5. The dialysate precursor composition of claim 1 wherein the physiologically-acceptable cation is selected from a group consisting of hydrogen, sodium, potassium, calcium, magnesium, and combinations thereof.

6. The dialysate precursor composition of claim 1 , further comprising a sugar selected from glucose, a poly(glucose), and fructose at a concentration of less than about 2,700 g/L.

7. The dialysate precursor composition of claim 1 wherein the citrate is selected from a group consisting of citric acid, sodium dihydrogen citrate, disodium hydrogen citrate, trisodium citrate, trisodium citrate dihydrate, potassium dihydrogen citrate, dipotassium hydrogen citrate, calcium citrate, and magnesium citrate; wherein the acetate is selected from a group consisting of acetic acid, sodium acetate, sodium acetate trihydrate, potassium acetate, calcium acetate, calcium acetate monohydrate, magnesium acetate, and magnesium acetate tetrahydrate; and wherein the lactate is selected from a group consisting of lactic acid, sodium lactate, potassium lactate, calcium lactate and magnesium lactate trihydrate.

8. The dialysate precursor composition of claim 1 wherein the water meets or exceeds the purity requirements established by the Association for the Advancement of Medical Instrumentation (AAMI) for dialysate, and all other components have at least United States Pharmacopeia (USP)-grade purity.

9. The dialysate precursor composition of claim 1 having a pH ranging from about 1 to about 6.5 at a temperature of about 15° C. to about 40° C.

10. The dialysate precursor composition of claim 1 comprising chloride at a concentration ranging from about 2,000 to about 5,000 mEq/L; citrate at a concentration ranging from about 70 to about 150 mEq/L; acetate at a concentration ranging from about 0.3 to about 125 mEq/L; at least one physiologically-acceptable cation selected from hydrogen, sodium at a concentration ranging from about 2,000 to about 5,000 mEq/L, potassium at a concentration of less than about 250 mEq/L, calcium at a concentration of less than about 250 mEq/L, and magnesium at a concentration of less than about 100 mEq/L; glucose at a concentration of less than about 2,700 g/L; and a therapeutically effective amount of ferric form of iron, where the composition at least meets the AAMI standard set for dialysate.

11. The dialysate precursor composition of claim 1 wherein the ferric form of iron is ferric citrate.

12. The dialysate precursor composition of claim 1 further comprising one or more trace elements.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 20, 2003
From: CALLAN, ROBIN; VAN SCHALKWIJK, WALTER A.; COLE, JAMES J.; AHMAD, SUHAIL
To: ADVANCED RENAL TECHNOLOGIES
Reel/Frame 014711/0752 →
Continuity (3)
Continuation In Part 0942162200 · Oct 19, 1999
Provisional Application 6010504900 · Oct 20, 1998
Related Publication 20040060865A1 · Apr 1, 2004